Sonic Healthcare
Sonic Healthcare is an Australian international healthcare company focused on medical laboratory, pathology, diagnostic imaging and primary care services.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Sonic Healthcare Limited is a Sydney-based healthcare company whose principal activities are medical laboratory services, anatomical pathology, diagnostic imaging and primary care. Its operating model combines large reference laboratories with networks of local collection centres, specialist pathology practices, radiology businesses, medical centres and physician relationships. The company serves hospitals, doctors, employers, insurers, governments and individual patients, with services ranging from routine blood testing to complex molecular, genetic, cytology and histopathology investigations. The company traces its roots to Douglass Laboratories and was listed on the Australian Securities Exchange in 1987 as Sonic Technology Australia Ltd. During the 1990s it used acquisitions and integrations to consolidate pathology practices across Australia. Clinpath Laboratories, Tan Pathology, Hanly Moir Pathology, Barratt and Smith Pathologists, Barratt Smith Moran Pathology and other regional operations became part of a progressively larger national network. In 1998, the acquisition of the SGS Medical Group expanded Sonic's presence across Australian pathology, New Zealand laboratory services and diagnostic imaging. The company formally adopted the Sonic Healthcare name in 1995, reflecting its widening healthcare scope. International expansion became central to the business in the 2000s. Sonic acquired The Doctors Laboratory in the United Kingdom in 2002 and built a substantial United States pathology platform through Clinical Pathology Laboratories and later acquisitions including American Esoteric Laboratories, Sunrise Medical Laboratories, CBLPath, Aurora Diagnostics and ProPath. In continental Europe, acquisitions of Schottdorf, Bioscientia, Medica, Labco and other laboratory groups established operations in Germany, Switzerland and Belgium. The company has generally retained local medical brands and professional structures rather than replacing every acquired business with a single consumer-facing identity. Alongside laboratory medicine, Sonic developed diagnostic imaging and primary care capabilities. Its imaging portfolio grew through businesses such as Queensland X-Ray, SKG Radiology, Castlereagh Imaging and later Australian imaging investments. Its primary-care activities include medical-centre networks and associated services operated through Independent Practitioner Network and related businesses. Sonic also expanded into workplace health, travel medicine, clinical trials and selected digital or specialist diagnostic partnerships. Sonic's scale is based on decentralized medical operations supported by group-wide systems, procurement, quality programs, information technology and management coordination. The company presents itself as a provider of medically led diagnostics, emphasizing professional autonomy, service quality and long-term relationships with referring clinicians. It operates in Australasia, North America and Europe, and describes itself as one of the largest listed medical companies in Australia and a major private laboratory provider in its principal overseas markets. Dr Colin Goldschmidt served as Sonic's chief executive officer and managing director for the first 38 years of the company's development. In 2025, Dr Jim Newcombe succeeded him in those roles. Sonic's current scope includes routine and specialized laboratory testing, pathology, imaging, primary care and related healthcare services. Its portfolio has also included strategic technology and distribution investments, such as the 2022 investment in Microba Life Sciences and collaborations involving microbiome testing and artificial-intelligence-enabled pathology solutions.
History
Sonic Healthcare developed from the Australian pathology practice Douglass Laboratories and entered the Australian Securities Exchange in 1987 as Sonic Technology Australia Ltd. Its early growth was driven by the consolidation of independent pathology practices. Douglass Laboratories opened an Adelaide branch in 1991, and Colin Goldschmidt became managing director of the laboratory group in 1993. During the middle of the decade, the company acquired Clinpath Laboratories, Tan Pathology, Pathlab, Hanly Moir Pathology, Barratt and Smith Pathologists and Barratt Smith Moran Pathology. The company changed its name to Sonic Healthcare Limited in 1995, while the Douglass and Hanly Moir operations were combined into Douglass Hanly Moir Pathology. By 1996, Sonic had become Australia's largest pathology group. A major step occurred in 1998 with the acquisition of the SGS Medical Group. The transaction added Sullivan Nicolaides Pathology, Northern Pathology, Melbourne Pathology, Diagnostic Services in Tasmania, several New Zealand laboratory businesses and the New Zealand Radiology Group. This created a large Australasian diagnostics platform and began the company's more significant involvement in imaging. Further Australian expansion included Australian Diagnostics Laboratories and Southern Pathology in 1999, followed by Hitech Pathology and a range of imaging and pathology acquisitions in 2000 and 2001. The group acquired Queensland X-Ray, SKG Radiology, Clinipath Pathology and other regional operators, broadening its geographic coverage and service mix. Internationalization accelerated in the 2000s. Sonic acquired The Doctors Laboratory in the United Kingdom in 2002 and entered Germany through a majority interest in the Schottdorf Group in 2003. It also acquired or combined with additional British, Australian and German operations and obtained a substantial interest in Independent Practitioner Network, expanding into primary care. In 2005, Sonic purchased an initial 82% interest in Clinical Pathology Laboratories in the United States and subsequently acquired the remaining 18%. The American platform grew through purchases including Muskogee Clinical Laboratory, The Cognoscenti Health Institute, Lookadoo Skyline Laboratories, American Esoteric Laboratories, Sunrise Medical Laboratories, CBLPath and Physician's Automated Laboratory. European growth proceeded in parallel. Sonic acquired Bioscientia Healthcare Group in Germany, Medica Laboratory Group in Switzerland, further interests in the Schottdorf Group, and other laboratory businesses in Germany, Switzerland and Belgium. The company also added imaging and primary-care assets in Australia and New Zealand. Management structures were developed to coordinate the enlarged international organization, including a German Sonic Executive Committee established in 2009. From 2011 onward, Sonic continued to expand through selected acquisitions and partnerships rather than relying only on domestic consolidation. It added Belgian, German, Swiss, American and Australian laboratories, acquired Medisupport in Switzerland and Klinisch Laboratorium Declerck in Belgium in 2015, and purchased Adelaide Pathology Partners, Medibank Workplace Health and Travel Doctor businesses in Australia. In the United States it formed diagnostic partnerships with Baptist Memorial Health Care, Western Connecticut Health Network, NYU Langone Health and ProMedica Health System. These arrangements complemented outright acquisitions by linking Sonic's laboratory expertise with local healthcare systems. The late 2010s and early 2020s brought further portfolio changes. Sonic acquired Aurora Diagnostics in the United States in 2019 and sold its interest in GLP systems in Germany. It later acquired Pathologie Hamburg, a majority interest in Epworth Medical Imaging in Victoria, Canberra Imaging Group and ProPath in Dallas. The company also took a majority stake in pathology-solutions developer Harrison.ai. In 2022, Sonic purchased 19.99% of Microba Life Sciences and agreed to help distribute Microba's microbiome-testing technology in Germany, the United Kingdom and Belgium, with non-exclusive distribution across additional Sonic markets. Throughout its development, Sonic has maintained a model in which local laboratory and medical brands operate within a broader international group. Its business now spans laboratory medicine, pathology, radiology, primary care, workplace and travel health, clinical trials and selected diagnostic technology relationships across Australia, New Zealand, the United States and Europe. Colin Goldschmidt led the company as chief executive and managing director from 1993 until 2025, when Jim Newcombe succeeded him.
- 2025
Leadership succession
[1]Jim Newcombe succeeded Colin Goldschmidt as chief executive officer and managing director.
- 2022
Invests in Microba Life Sciences
[1]Sonic acquired a 19.99% stake in Microba Life Sciences and formed a strategic relationship concerning microbiome testing technology.
- 2019
Acquires Aurora Diagnostics
[1]The acquisition expanded Sonic's American pathology platform.
- 2015
Expands Swiss, Belgian and Australian operations
[1]Sonic acquired Medisupport in Switzerland, Klinisch Laboratorium Declerck in Belgium, Adelaide Pathology Partners and additional Australian health businesses.
- 2013
Acquires Labco
[1]The Labco acquisition strengthened Sonic's European laboratory presence.
- 2007
Adds major European laboratory groups
[1]The company acquired Medica Laboratory Group, Bioscientia Healthcare Group and the remaining equity in the Schottdorf Group.
- 2005
Expands into US regional pathology
[1]Sonic acquired an 82% interest in Clinical Pathology Laboratories and later acquired the remaining shares.
- 2002
Enters the United Kingdom through The Doctors Laboratory
[1]Sonic acquired The Doctors Laboratory, establishing a significant British private pathology operation.
- 1998
Acquires SGS Medical Group
[1]The transaction created a major Australasian pathology and diagnostic-imaging network.
- 1995
Adopts the Sonic Healthcare name
[1]The company formally changed its name from Sonic Technology Australia to Sonic Healthcare Limited.
Products and positioning
A medically led, international diagnostics and healthcare-services group combining local laboratory and clinical brands with centralized scale, technology, quality systems and operational support.
Medical laboratory services
Clinical laboratory testing
Sonic operates laboratories providing routine and specialized clinical testing for blood, urine, tissue and other specimens. The service base supports hospitals, general practitioners, specialists, employers and patients, with local collection networks linked to regional and reference laboratories. Testing spans common diagnostic work as well as higher-complexity investigations performed within the group's national and international laboratory infrastructure.
Pathology
Anatomical pathology
The group's anatomical pathology activities examine tissue and cellular samples to assist diagnosis, treatment planning and disease monitoring. Its portfolio includes histopathology and cytopathology, with specialist practices operating under local brands in Australia, the United States and Europe. The service is closely connected to hospitals, surgeons, oncologists and other referring clinicians.
Specialty diagnostics
Molecular and specialist diagnostics
Sonic's laboratories provide specialized diagnostic services in areas including molecular testing, genetics, microbiology and other esoteric investigations. These capabilities are delivered through large reference laboratories and specialist pathology organizations. The company has also pursued partnerships and investments involving microbiome analysis and artificial-intelligence-enabled pathology technology.
Radiology
Diagnostic imaging
Diagnostic imaging is delivered through radiology practices acquired or developed across Australia and New Zealand, including businesses associated with Queensland X-Ray, SKG Radiology, Castlereagh Imaging and other regional groups. Imaging services complement laboratory medicine by providing non-laboratory diagnostic investigations for community, specialist and hospital patients.
Primary healthcare
Primary care and medical centres
Through Independent Practitioner Network and related operations, Sonic has participated in primary care, medical-centre and associated physician services. These activities extend the group beyond laboratory and imaging diagnostics and provide community-based healthcare access, although the scale and composition of the primary-care portfolio have changed over time.
Occupational and travel medicine
Workplace and travel health
Sonic has operated workplace-health and travel-medicine businesses, including Medibank Workplace Health and Travel Doctor operations acquired in Australia. These services address employer health programs, occupational assessments, travel consultations and related preventive-care needs.
Brand decisions
2022
Microbiome-testing strategic allianceStrategyBackground
Sonic sought exposure to emerging diagnostic technologies and new testing categories.
Action taken
It acquired a 19.99% interest in Microba Life Sciences and agreed to distribute Microba's microbiome-testing technology in selected European markets, with non-exclusive distribution in additional Sonic markets.
Aftermath
The arrangement connected Microba's technology with Sonic's international laboratory network.
2019
Acquisition of Aurora DiagnosticsM&ABackground
Sonic continued to deepen its United States pathology and specialty-diagnostics operations.
Action taken
The company acquired Aurora Diagnostics in the United States.
Aftermath
Aurora became part of Sonic's expanding American pathology platform.
2013
Acquisition of LabcoM&ABackground
Sonic was consolidating its European laboratory operations and seeking additional scale in continental markets.
Action taken
Sonic acquired Labco S.A. Group in Germany and associated European operations.
Aftermath
The deal broadened Sonic's European laboratory footprint.
2005
Acquisition of Clinical Pathology LaboratoriesM&ABackground
Sonic aimed to establish a substantial United States platform in regional and reference pathology.
Action taken
It acquired an 82% interest in Clinical Pathology Laboratories and later purchased the remaining 18%.
Aftermath
Clinical Pathology Laboratories became a foundation of Sonic's American laboratory network.
2002
Acquisition of The Doctors LaboratoryM&ABackground
Sonic was beginning to build an international laboratory network outside Australasia.
Action taken
The company acquired The Doctors Laboratory, a major private pathology practice in the United Kingdom.
Aftermath
The purchase established a durable Sonic presence in the British private pathology market.
1998
Acquisition of SGS Medical GroupM&ABackground
Sonic sought to expand beyond its existing Australian pathology base and build a broader Australasian diagnostics platform.
Action taken
It acquired the SGS Medical Group, adding pathology, laboratory and radiology operations in Australia and New Zealand.
Aftermath
The transaction made Sonic the largest diagnostic group in Australasia and marked a significant expansion into imaging.
Recent events
- 2025
Sonic Healthcare appoints Jim Newcombe as chief executive and managing director[1]
Leadership change
Jim Newcombe succeeded Colin Goldschmidt, who had led Sonic Healthcare as chief executive and managing director for 38 years.
- 2022
Sonic Healthcare acquires a strategic stake in Microba Life Sciences[1]
M&A
Sonic acquired a 19.99% interest in Queensland-based Microba Life Sciences and agreed a strategic distribution relationship for microbiome testing technology.
- 2021
Sonic Healthcare expands its United States pathology portfolio through ProPath[1]
M&A
The company acquired ProPath, a Dallas-based pathology business, continuing its expansion in specialized United States diagnostics.
- 2019
Sonic Healthcare acquires Aurora Diagnostics[1]
M&A
Sonic acquired Aurora Diagnostics in the United States, strengthening its American pathology and specialty-diagnostics platform.
- 2013
Sonic Healthcare acquires Labco[1]
M&A
The acquisition of Labco expanded Sonic's European laboratory operations and added scale to its continental diagnostics network.
- 2005
Sonic Healthcare acquires Clinical Pathology Laboratories[1]
M&A
Sonic acquired an initial majority interest in Clinical Pathology Laboratories, one of the largest privately owned regional pathology laboratories in the United States, and later acquired the remaining interest.
- 2002
Sonic Healthcare acquires The Doctors Laboratory[1]
M&A
The purchase of The Doctors Laboratory established a major Sonic presence in the United Kingdom's private pathology market.
- 1998
Sonic Healthcare builds a broad Australasian diagnostic network[1]
M&A
The acquisition of the SGS Medical Group brought together pathology, laboratory and imaging operations across Australia and New Zealand.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sonic-healthcare · Editorial policy · How profiles are compiled